20:11 , Mar 10, 2017 |  BC Week In Review  |  Financial News

TG Therapeutics completes follow-on

On March 9, cancer and autoimmune company TG Therapeutics Inc. (NASDAQ:TGTX) raised $50 million through the sale of 5.1 million shares at $9.75 in a follow-on underwritten by Jefferies, SunTrust, Ladenburg Thalmann, H.C. Wainwright, Aegis...
20:16 , Mar 9, 2017 |  BC Extra  |  Financial News

TG raises $50M in follow-on

TG Therapeutics Inc. (NASDAQ:TGTX) added $1.65 (16%) to $11.80 on Thursday after it raised $50 million through the sale of 5.1 million shares at $9.75 in a follow-on underwritten by Jefferies, SunTrust, Ladenburg Thalmann, H.C....
20:32 , Feb 3, 2017 |  BC Week In Review  |  Financial News

Mustang Bio completes venture financing

Cancer play Mustang Bio Inc. (New York, N.Y.), a subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO, New York, N.Y.), raised $94.5 million in a private placement on Feb. 2. OPN Capital Markets was the placement agent. Mustang...
23:35 , Feb 2, 2017 |  BC Extra  |  Financial News

Mustang raises $94.5M in private placement

Fortress Biotech Inc. (NASDAQ:FBIO) said its Mustang Bio Inc. (New York, N.Y.) subsidiary raised $94.5 million in a private placement. OPN Capital Markets was the sole placement agent. In May, Mustang said its MB-101 led to...
07:00 , Oct 13, 2016 |  BC Innovations  |  Product R&D

Elastic bones

A group at Northwestern University has created a "hyperelastic bone" scaffold to address the need for a bone-inducing material that is easily manufactured, low cost and easy to manipulate during surgery. While the short-term goal...
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
03:53 , Oct 22, 2014 |  BC Extra  |  Politics & Policy

FDA backs further study of kidney biomarkers

FDA issued its first Letter of Support for two kidney biomarkers identified by the Predictive Safety Testing Consortium (PSTC) of the Critical Path Institute (C-Path). Elevated levels of the two biomarkers, osteopontin (OPN) and neutrophil...
07:00 , May 24, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Musculoskeletal disease Family with sequence similarity 20 member C (FAM20C) In vitro studies identified FAM20C as...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Financial News

TG Therapeutics completes private placement of convertible preferred stock and warrants

TG Therapeutics Inc. (OTCBB: TGTX), New York, N.Y.   Business: Endocrine/Metabolic, Drug delivery   Date completed: 2/24/12   Type: Private placement of convertible preferred stock and warrants   Raised: $4.1 million   Shares: 206,229   Price: $20   Placement agent: OPN...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Laboratoire francais, TG Therapeutics deal

TG Therapeutics said that in January it exercised an exclusive, worldwide option to license from former parent company LFB rights to develop and commercialize ublituximab ( LFB-R603). The chimeric recombinant mAb against CD20...